Outlook Therapeutics (OTLK) Receives Nasdaq Non-compliance Notice

On April 1, 2024, Outlook Therapeutics (NASDAQ: OTLK) received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from March 14, 2024 to March 28, 2024, the closing bid price of the Company’s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.

You May Also Be Interested In

• WD-40 names Keith Stauffer as incoming CFO
• FirstEnergy names Jon Dormo VP of generation project development
• Adobe names Anil Chakravarthy as CEO, Narayen to become chair